High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

被引:406
|
作者
Lisio, Michael-Antony [1 ]
Fu, Lili [1 ]
Goyeneche, Alicia [1 ]
Gao, Zu-hua [1 ]
Telleria, Carlos [1 ]
机构
[1] McGill Univ, Dept Pathol, Expt Pathol Unit, Montreal, PQ H3A 2B4, Canada
关键词
high-grade serous ovarian cancer; cortical inclusion cysts; serous tubular intra-epithelial carcinoma; ovarian surface epithelium; homologous recombination; BRCA; mutant p53; genetically-engineered mouse models; debulking surgery; chemotherapy; TUBAL INTRAEPITHELIAL CARCINOMA; OLAPARIB MAINTENANCE THERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; GROSS RESIDUAL DISEASE; RANDOMIZED PHASE-III; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; OPEN-LABEL; TP53; MUTATIONS; DOUBLE-BLIND;
D O I
10.3390/ijms20040952
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Among a litany of malignancies affecting the female reproductive tract, that of the ovary is the most frequently fatal. Moreover, while the steady pace of scientific discovery has fuelled recent ameliorations in the outcomes of many other cancers, the rates of mortality for ovarian cancer have been stagnant since around 1980. Yet despite the grim outlook, progress is being made towards better understanding the fundamental biology of this disease and how its biology in turn influences clinical behaviour. It has long been evident that ovarian cancer is not a unitary disease but rather a multiplicity of distinct malignancies that share a common anatomical site upon presentation. Of these, the high-grade serous subtype predominates in the clinical setting and is responsible for a disproportionate share of the fatalities from all forms of ovarian cancer. This review aims to provide a detailed overview of the clinical-pathological features of ovarian cancer with a particular focus on the high-grade serous subtype. Along with a description of the relevant clinical aspects of this disease, including novel trends in treatment strategies, this text will inform the reader of recent updates to the scientific literature regarding the origin, aetiology and molecular-genetic basis of high-grade serous ovarian cancer (HGSOC).
引用
收藏
页数:33
相关论文
共 50 条
  • [21] Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer
    Cardillo, Nicholas
    Devor, Eric J.
    Pedra Nobre, Silvana
    Newtson, Andreea
    Leslie, Kimberly
    Bender, David P.
    Smith, Brian J.
    Goodheart, Michael J.
    Gonzalez-Bosquet, Jesus
    CANCERS, 2022, 14 (14)
  • [22] High-grade serous ovarian cancer (HGSOC) with fallopian tube involvement
    Tanase, Adina Elena
    Solomon-condriuc, Iustina Petra
    Mogos, Raluca Anamaria
    Costachescu, Gabriel
    David, Cristina
    Buzduga, Catalin Mihai
    Scripcariu, Dragos Viorel
    Costea, Claudia Florida
    Cucu, Andrei Ionut
    Tanase, Gabriel Valentin
    Tanase, Daniela Maria
    Nemescu, Dragos
    Dumitrescu, Ana Maria
    Carauleanu, Alexandru
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2024, 65 (02) : 325 - 329
  • [23] Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer
    Al-Dossary, Amal A.
    Tawfik, Essam A.
    Isichei, Adaugo C.
    Sun, Xin
    Li, Jiahe
    Alshehri, Abdullah A.
    Alomari, Munther
    Almughem, Fahad A.
    Aldossary, Ahmad M.
    Sabit, Hussein
    Almalik, Abdulaziz M.
    CANCERS, 2021, 13 (12)
  • [24] The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
    Yan, Shunfei
    Frank, Daniel
    Son, Jinbae
    Hannan, Katherine M.
    Hannan, Ross D.
    Chan, Keefe T.
    Pearson, Richard B.
    Sanij, Elaine
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (01):
  • [25] Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
    Ivy, S. Percy
    Kunos, Charles A.
    Arnaldez, Fernanda I.
    Kohn, Elise C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (09) : 771 - 785
  • [26] Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
    Zhang, Hui
    Liu, Tao
    Zhang, Zhen
    Payne, Samuel H.
    Zhang, Bai
    McDermott, Jason E.
    Zhou, Jian-Ying
    Petyuk, Vladislav A.
    Chen, Li
    Ray, Debjit
    Sun, Shisheng
    Yang, Feng
    Chen, Lijun
    Wang, Jing
    Shah, Punit
    Cha, Seong Won
    Aiyetan, Paul
    Woo, Sunghee
    Tian, Yuan
    Gritsenko, Marina A.
    Clauss, Therese R.
    Choi, Caitlin
    Monroe, Matthew E.
    Thomas, Stefani
    Nie, Song
    Wu, Chaochao
    Moore, Ronald J.
    Yu, Kun-Hsing
    Tabb, David L.
    Fenyo, David
    Bafna, Vineet
    Wang, Yue
    Rodriguez, Henry
    Boja, Emily S.
    Hiltke, Tara
    Rivers, Robert C.
    Sokoll, Lori
    Zhu, Heng
    Shih, Ie-Ming
    Cope, Leslie
    Pandey, Akhilesh
    Zhang, Bing
    Snyder, Michael P.
    Levine, Douglas A.
    Smith, Richard D.
    Chan, Daniel W.
    Rodland, Karin D.
    CELL, 2016, 166 (03) : 755 - 765
  • [27] Immunohistochemical Expression of p53 Gene and Clinicopathological Assessment of Low-grade Serous Ovarian Cancer and High-grade Serous Ovarian Cancer: A Cohort Study
    Bazard, Geeta
    Vashist, Minakshi
    Singh, Sunita
    Rohilla, Gulshan
    Paliwal, Nidhi
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2024, 18 (12) : QC10 - QC14
  • [29] Principles of dormancy evident in high-grade serous ovarian cancer
    Trevor G. Shepherd
    Frederick A. Dick
    Cell Division, 17
  • [30] Evolution of platinum resistance in high-grade serous ovarian cancer
    Cooke, Susanna L.
    Brenton, James D.
    LANCET ONCOLOGY, 2011, 12 (12) : 1169 - 1174